A Multi-centre, Double-blind, Parallel-group, Randomised, Placebo Controlled Phase II a Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Different Doses of Orally Administered BI 1467335 During a 12-week Treatment Period Compared to Placebo in Patients With Clinical Evidence of NASH
Latest Information Update: 22 Jan 2024
At a glance
- Drugs BI 1467335 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacodynamics
- Sponsors Boehringer Ingelheim
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 18 Dec 2019 Results presented in a Pharmaxis media release.
- 27 Jun 2019 Status changed from active, no longer recruiting to completed.